Clinical outcomes of heart transplantation using hepatitis c-viremic donors: A systematic review with meta-analysis

Heart transplantation (HTx) from hepatitis C virus (HCV)-viremic donors to nonviremic recipients decreases mortality and costs. Consequently, many transplant centers have reported their results using this strategy. Hence, there is a need for an outcome analysis. We performed a systematic review with...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of heart and lung transplantation Vol. 41; no. 4; pp. 538 - 549
Main Authors Villegas-Galaviz, Josue, Anderson, Eve, Guglin, Maya
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Heart transplantation (HTx) from hepatitis C virus (HCV)-viremic donors to nonviremic recipients decreases mortality and costs. Consequently, many transplant centers have reported their results using this strategy. Hence, there is a need for an outcome analysis. We performed a systematic review with meta-analysis. In August 2020, we searched PubMed and EMBASE for publications containing data of nonviremic recipients who underwent HTx from HCV-viremic donors once direct-acting antiviral (DAA) therapy had become available (≥2014). We identified 398 publications, 13 of which met inclusion criteria, and analyzed the outcomes of 195 recipients. The HCV-transmission rate was >97% but, the cure rate was 100% with DAA therapy. The 6 and 12-month survival were 95.6% and 92.9%, respectively. Of 10 deaths reported, none were associated with HCV infection. The acute cellular rejection (ACR) rate was 31.1%. The overall DAA failure rate was 1.1%, defined as the need to alter the initial DAA therapy due to failure to cure HCV. However, the DAA failure rate was 0% when the DAA therapy was started within the first 2 weeks post-HTx. No statistically significant differences in HCV cure rates, survivals, ACR rates, and DAA failure rates were observed when outcomes were stratified by therapeutic approach type (i.e., a prophylactic approach in which DAA was given to the recipient before confirming HCV-transmission vs a reactive approach, in which DAA was given to the recipient only after an HCV-transmission was confirmed). Excellent clinical outcomes have been observed in nonviremic recipients of HTx from HCV-viremic donors since DAA had become available.
AbstractList BACKGROUNDHeart transplantation (HTx) from hepatitis C virus (HCV)-viremic donors to nonviremic recipients decreases mortality and costs. Consequently, many transplant centers have reported their results using this strategy. Hence, there is a need for an outcome analysis. METHODSWe performed a systematic review with meta-analysis. In August 2020, we searched PubMed and EMBASE for publications containing data of nonviremic recipients who underwent HTx from HCV-viremic donors once direct-acting antiviral (DAA) therapy had become available (≥2014). RESULTSWe identified 398 publications, 13 of which met inclusion criteria, and analyzed the outcomes of 195 recipients. The HCV-transmission rate was >97% but, the cure rate was 100% with DAA therapy. The 6 and 12-month survival were 95.6% and 92.9%, respectively. Of 10 deaths reported, none were associated with HCV infection. The acute cellular rejection (ACR) rate was 31.1%. The overall DAA failure rate was 1.1%, defined as the need to alter the initial DAA therapy due to failure to cure HCV. However, the DAA failure rate was 0% when the DAA therapy was started within the first 2 weeks post-HTx. No statistically significant differences in HCV cure rates, survivals, ACR rates, and DAA failure rates were observed when outcomes were stratified by therapeutic approach type (i.e., a prophylactic approach in which DAA was given to the recipient before confirming HCV-transmission vs a reactive approach, in which DAA was given to the recipient only after an HCV-transmission was confirmed). CONCLUSIONSExcellent clinical outcomes have been observed in nonviremic recipients of HTx from HCV-viremic donors since DAA had become available.
Heart transplantation (HTx) from hepatitis C virus (HCV)-viremic donors to nonviremic recipients decreases mortality and costs. Consequently, many transplant centers have reported their results using this strategy. Hence, there is a need for an outcome analysis. We performed a systematic review with meta-analysis. In August 2020, we searched PubMed and EMBASE for publications containing data of nonviremic recipients who underwent HTx from HCV-viremic donors once direct-acting antiviral (DAA) therapy had become available (≥2014). We identified 398 publications, 13 of which met inclusion criteria, and analyzed the outcomes of 195 recipients. The HCV-transmission rate was >97% but, the cure rate was 100% with DAA therapy. The 6 and 12-month survival were 95.6% and 92.9%, respectively. Of 10 deaths reported, none were associated with HCV infection. The acute cellular rejection (ACR) rate was 31.1%. The overall DAA failure rate was 1.1%, defined as the need to alter the initial DAA therapy due to failure to cure HCV. However, the DAA failure rate was 0% when the DAA therapy was started within the first 2 weeks post-HTx. No statistically significant differences in HCV cure rates, survivals, ACR rates, and DAA failure rates were observed when outcomes were stratified by therapeutic approach type (i.e., a prophylactic approach in which DAA was given to the recipient before confirming HCV-transmission vs a reactive approach, in which DAA was given to the recipient only after an HCV-transmission was confirmed). Excellent clinical outcomes have been observed in nonviremic recipients of HTx from HCV-viremic donors since DAA had become available.
Author Anderson, Eve
Villegas-Galaviz, Josue
Guglin, Maya
Author_xml – sequence: 1
  givenname: Josue
  orcidid: 0000-0001-5803-3188
  surname: Villegas-Galaviz
  fullname: Villegas-Galaviz, Josue
  email: jvillegasgal@gmail.com
  organization: Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana
– sequence: 2
  givenname: Eve
  orcidid: 0000-0003-0109-6350
  surname: Anderson
  fullname: Anderson, Eve
  organization: Cardiothoracic Transplant, Indiana University Health Methodist Hospital, Indianapolis, Indiana
– sequence: 3
  givenname: Maya
  surname: Guglin
  fullname: Guglin, Maya
  organization: Heart Failure/Heart Transplantation/MCS Services, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35153130$$D View this record in MEDLINE/PubMed
BookMark eNp9kEtrHDEMgE1IaB7tPyjFx15ma9njefQQCEtfEOglPRuPR5N4mbG3lidh_30cNs2xIJCMP0nou2SnIQZk7COIDQhovuw2D2jnNWykkHIjoIQ4YRegdVspgPa01EKrStZ9d84uiXZCCKm0fMfOlQatQIkLRtvZB-_szOOaXVyQeJx4mZwyz8kG2s82ZJt9DHwlH-7L3748syfuqkefcPGOjzHERF_5DacDZVwK4HjCR49P_MnnB75gtpUNdj6Qp_fsbLIz4YfXfMX-fP92t_1Z3f7-8Wt7c1s51chcTThNqu1gqPt6BGfRKamFGOsB-q7XVsIwoR2bpm36duzEIJp-GKUG1zuNMKgr9vk4d5_i3xUpm8WTw7lchHElIxvZNb0G6AtaH1GXIlHCyeyTX2w6GBDmRbfZmaNu86LbCCghStun1w3rsOD41vTPbwGujwCWO4uOZMh5DA7HYs5lM0b__w3Pb2eW_Q
CitedBy_id crossref_primary_10_1097_MAT_0000000000001925
crossref_primary_10_1016_S0140_6736_23_01320_X
crossref_primary_10_1038_s41569_023_00902_1
crossref_primary_10_1097_MOT_0000000000001060
crossref_primary_10_1111_ctr_15111
Cites_doi 10.1016/j.cardfail.2017.08.448
10.1016/j.healun.2019.08.010
10.1056/NEJMoa1812406
10.1111/ctr.13308
10.1111/ctr.13764
10.1111/ajt.15676
10.1111/ajt.14381
10.1097/TXD.0000000000000928
10.1002/hep.31011
10.1016/S2468-1253(20)30081-9
10.1097/CRD.0000000000000255
10.1016/S2468-1253(19)30240-7
10.1016/j.healun.2019.01.313
10.1016/j.healun.2020.03.004
10.1016/S0016-5085(20)33980-9
10.1002/hep.31060
10.1371/journal.pmed.1000097
10.1111/ajt.15857
10.1016/j.transproceed.2019.01.025
10.1161/CIRCHEARTFAILURE.118.005276
10.1111/ajt.15311
10.1016/j.healun.2019.08.019
10.1161/JAHA.119.014495
10.1001/jama.296.15.1843
10.1111/ctr.13989
10.1016/S1053-2498(00)00062-0
10.1034/j.1600-6143.2002.20508.x
10.1001/jamacardio.2019.4748
10.1053/j.jvca.2019.12.012
10.7326/M16-2575
ContentType Journal Article
Copyright 2022 International Society for Heart and Lung Transplantation
Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2022 International Society for Heart and Lung Transplantation
– notice: Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.healun.2022.01.010
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1557-3117
EndPage 549
ExternalDocumentID 10_1016_j_healun_2022_01_010
35153130
S1053249822000158
Genre Meta-Analysis
Systematic Review
Journal Article
GroupedDBID ---
--K
.1-
.FO
.GJ
0R~
123
1B1
1P~
1~5
29K
4.4
457
4G.
53G
5RE
5VS
7-5
71M
AAEDT
AAEDW
AAIAV
AALRI
AAQFI
AAQQT
AAQXK
AAXUO
ABFRF
ABJNI
ABLJU
ABMAC
ABOCM
ACGFO
ACIUM
ADBBV
ADMUD
ADPAM
AEFWE
AENEX
AEVXI
AFRHN
AFTJW
AGZHU
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
ALXNB
AMRAJ
ASPBG
AVWKF
AZFZN
BELOY
C5W
CS3
D-I
DU5
EBS
EFJIC
EJD
F5P
FDB
FEDTE
FGOYB
GBLVA
HVGLF
HZ~
IHE
J1W
J5H
KOM
M41
MO0
N9A
NQ-
O9-
OA-
OL.
R2-
RIG
ROL
RPZ
SDG
SEL
SES
SSZ
UV1
XH2
Z5R
ZA5
ZGI
ZXP
ADVLN
AFCTW
AFJKZ
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
ACRPL
ADNMO
CITATION
7X8
ID FETCH-LOGICAL-c362t-feff3781b494d1caec32500d4b19895a21bfead667697d80b069bd251c9c5e1b3
ISSN 1053-2498
IngestDate Wed Dec 04 02:22:37 EST 2024
Fri Dec 06 04:03:54 EST 2024
Sat Sep 28 08:19:05 EDT 2024
Fri Feb 23 02:41:17 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords hepatitis c viremic donors
NAT
heart transplantation
hepatitis c non-viremic recipients
DAA
cardiac transplantation
SVR12
HTx
ISHLT
NAT+Ds
direct-acting antivirals
ACR
hepatitis c virus
NAT-Rs
HCV
IPD
nucleic acid amplification test
Language English
License Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c362t-feff3781b494d1caec32500d4b19895a21bfead667697d80b069bd251c9c5e1b3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ORCID 0000-0001-5803-3188
0000-0003-0109-6350
PMID 35153130
PQID 2628695119
PQPubID 23479
PageCount 12
ParticipantIDs proquest_miscellaneous_2628695119
crossref_primary_10_1016_j_healun_2022_01_010
pubmed_primary_35153130
elsevier_sciencedirect_doi_10_1016_j_healun_2022_01_010
PublicationCentury 2000
PublicationDate April 2022
2022-04-00
20220401
PublicationDateYYYYMMDD 2022-04-01
PublicationDate_xml – month: 04
  year: 2022
  text: April 2022
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of heart and lung transplantation
PublicationTitleAlternate J Heart Lung Transplant
PublicationYear 2022
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Ghany, Morgan (bib0008) 2020; 71
Bethea, Gaj, Gustafson (bib0009) 2019; 4
Frager, Dhand, Gass (bib0012) 2019; 27
Schlendorf, Zalawadiya, Shah (bib0015) 2019; 5
Marelli, Bresson, Laks (bib0025) 2002; 2
Gottlieb, Sam, Wada (bib0019) 2017; 23
Kapila, Menon, Al-Khalloufi (bib0020) 2020; 72
Chacon, Adams, Kassel, Markin (bib0006) 2019; 34
Gasink, Blumberg, Localio, Desai, Israni, Lautenbach (bib0005) 2006; 296
McLean, Reese, Acker (bib0014) 2019; 19
Aslam, Yumul, Mariski, Pretorius, Adler (bib0017) 2019; 38
Levitsky, Formica, Bloom (bib0001) 2017; 17
Faust, Weile, Fujita (bib0018) 2019; 51
Moher, Liberati, Tetzlaff, Altman, Group (bib0022) 2009; 6
Burgess, Hussaini, Yoshida (bib0024) 2016; 15
Woolley, Singh, Goldberg (bib0011) 2019; 380
Reyentovich, Gidea, Smith (bib0016) 2020; 34
Prakash, Wainana, Trageser (bib0031) 2020; 20
Logan, Yumul, Aslam, Martin (bib0003) 2019; 38
Bruno, Nicole, Nila (bib0027) 2019; 5
Falade-Nwulia, Suarez-Cuervo, Nelson, Fried, Segal, Sulkowski (bib0007) 2017; 166
Aslam, Grossi, Schlendorf (bib0023) 2020; 39
Moayedi, Fan, Gulamhusein (bib0030) 2018; 11
Gernhofer, Brambatti, Greenberg, Adler, Aslam, Pretorius (bib0002) 2019; 38
Colvin, Smith, Hadley (bib0028) 2020; 20
Wang, Li, Bethea, Myoung, Tuohy, Chung (bib0004) 2020; 158
Feld, Cypel, Kumar (bib0010) 2020; 5
Pfau, Rho, DeNofrio (bib0026) 2000; 19
Morris, Adlam, Padanilam (bib0013) 2020; 34
Moayedi, Gulamhusein, Ross, Teuteberg, Khush (bib0021) 2018; 32
Kilic, Hickey, Mathier (bib0029) 2020; 9
Gernhofer (10.1016/j.healun.2022.01.010_bib0002) 2019; 38
Kilic (10.1016/j.healun.2022.01.010_bib0029) 2020; 9
Bruno (10.1016/j.healun.2022.01.010_bib0027) 2019; 5
Logan (10.1016/j.healun.2022.01.010_bib0003) 2019; 38
Levitsky (10.1016/j.healun.2022.01.010_bib0001) 2017; 17
Falade-Nwulia (10.1016/j.healun.2022.01.010_bib0007) 2017; 166
Aslam (10.1016/j.healun.2022.01.010_bib0017) 2019; 38
Moayedi (10.1016/j.healun.2022.01.010_bib0021) 2018; 32
Frager (10.1016/j.healun.2022.01.010_bib0012) 2019; 27
Marelli (10.1016/j.healun.2022.01.010_bib0025) 2002; 2
Colvin (10.1016/j.healun.2022.01.010_bib0028) 2020; 20
Moayedi (10.1016/j.healun.2022.01.010_bib0030) 2018; 11
Kapila (10.1016/j.healun.2022.01.010_bib0020) 2020; 72
Schlendorf (10.1016/j.healun.2022.01.010_bib0015) 2019; 5
Prakash (10.1016/j.healun.2022.01.010_bib0031) 2020; 20
Faust (10.1016/j.healun.2022.01.010_bib0018) 2019; 51
Moher (10.1016/j.healun.2022.01.010_bib0022) 2009; 6
McLean (10.1016/j.healun.2022.01.010_bib0014) 2019; 19
Gottlieb (10.1016/j.healun.2022.01.010_bib0019) 2017; 23
Burgess (10.1016/j.healun.2022.01.010_bib0024) 2016; 15
Feld (10.1016/j.healun.2022.01.010_bib0010) 2020; 5
Morris (10.1016/j.healun.2022.01.010_bib0013) 2020; 34
Chacon (10.1016/j.healun.2022.01.010_bib0006) 2019; 34
Aslam (10.1016/j.healun.2022.01.010_bib0023) 2020; 39
Pfau (10.1016/j.healun.2022.01.010_bib0026) 2000; 19
Woolley (10.1016/j.healun.2022.01.010_bib0011) 2019; 380
Ghany (10.1016/j.healun.2022.01.010_bib0008) 2020; 71
Reyentovich (10.1016/j.healun.2022.01.010_bib0016) 2020; 34
Wang (10.1016/j.healun.2022.01.010_bib0004) 2020; 158
Gasink (10.1016/j.healun.2022.01.010_bib0005) 2006; 296
Bethea (10.1016/j.healun.2022.01.010_bib0009) 2019; 4
References_xml – volume: 38
  start-page: 1178
  year: 2019
  end-page: 1188
  ident: bib0002
  article-title: The impact of using hepatitis C virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate
  publication-title: J Heart Lung Transplant
  contributor:
    fullname: Pretorius
– volume: 5
  start-page: 167
  year: 2019
  end-page: 174
  ident: bib0015
  article-title: Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C
  publication-title: JAMA Cardiol
  contributor:
    fullname: Shah
– volume: 380
  start-page: 1606
  year: 2019
  end-page: 1617
  ident: bib0011
  article-title: Heart and lung transplants from HCV infected donors to uninfected recipients
  publication-title: N Engl J Med
  contributor:
    fullname: Goldberg
– volume: 158
  year: 2020
  ident: bib0004
  article-title: Implementation of HCV+ donor heart protocol produces net overall cost savings in cardiac transplantation
  publication-title: Gastroenterology
  contributor:
    fullname: Chung
– volume: 27
  start-page: 179
  year: 2019
  end-page: 181
  ident: bib0012
  article-title: Heart transplantation for hepatitis C virus non-viremic recipients from hepatitis C virus viremic donors
  publication-title: Cardiol Rev
  contributor:
    fullname: Gass
– volume: 20
  start-page: 2867
  year: 2020
  end-page: 2875
  ident: bib0031
  article-title: Local and regional variability in utilization and allocation of hepatitis C virus-infected hearts for transplantation
  publication-title: Am J Transplant
  contributor:
    fullname: Trageser
– volume: 166
  start-page: 637
  year: 2017
  end-page: 648
  ident: bib0007
  article-title: Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review
  publication-title: Ann Intern Med
  contributor:
    fullname: Sulkowski
– volume: 15
  start-page: 154
  year: 2016
  end-page: 159
  ident: bib0024
  article-title: Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: a concise review
  publication-title: Ann Hepatol
  contributor:
    fullname: Yoshida
– volume: 38
  start-page: S132
  year: 2019
  ident: bib0003
  article-title: Cost effectiveness of using hepatitis C Virus (HCV)-viremic hearts for transplantation into HCV-negative recipients
  publication-title: J Heart Lung Transplant
  contributor:
    fullname: Martin
– volume: 5
  start-page: 649
  year: 2020
  end-page: 657
  ident: bib0010
  article-title: Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study
  publication-title: Lancet Gastroenterol Hepatol
  contributor:
    fullname: Kumar
– volume: 34
  start-page: e13764
  year: 2020
  ident: bib0013
  article-title: Hepatitis C donor viremic cardiac transplantation: a practical approach
  publication-title: Clin Transplant
  contributor:
    fullname: Padanilam
– volume: 72
  start-page: 32
  year: 2020
  end-page: 41
  ident: bib0020
  article-title: Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus–negative recipients: a real-world experience
  publication-title: Hepatology
  contributor:
    fullname: Al-Khalloufi
– volume: 19
  start-page: 2533
  year: 2019
  end-page: 2542
  ident: bib0014
  article-title: Transplanting hepatitis C virus-infected hearts into uninfected recipients: a single-arm trial
  publication-title: Am J Transplant
  contributor:
    fullname: Acker
– volume: 20
  start-page: 340
  year: 2020
  end-page: 426
  ident: bib0028
  article-title: OPTN/SRTR 2018 annual data report: heart
  publication-title: Am J Transplant
  contributor:
    fullname: Hadley
– volume: 19
  start-page: 350
  year: 2000
  end-page: 354
  ident: bib0026
  article-title: Hepatitis C transmission and infection by orthotopic heart transplantation
  publication-title: J Heart Lung Transplant
  contributor:
    fullname: DeNofrio
– volume: 296
  start-page: 1843
  year: 2006
  end-page: 1850
  ident: bib0005
  article-title: Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients
  publication-title: JAMA
  contributor:
    fullname: Lautenbach
– volume: 34
  start-page: e13989
  year: 2020
  ident: bib0016
  article-title: Outcomes of the treatment with glecaprevir/pibrentasvir following heart transplantation utilizing hepatitis C viremic donors
  publication-title: Clin Transplant
  contributor:
    fullname: Smith
– volume: 23
  start-page: 765
  year: 2017
  end-page: 767
  ident: bib0019
  article-title: Rational heart transplant from a hepatitis C donor: new antiviral weapons conquer the trojan horse
  publication-title: J Card Fail
  contributor:
    fullname: Wada
– volume: 17
  start-page: 2790
  year: 2017
  end-page: 2802
  ident: bib0001
  article-title: The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation
  publication-title: Am J Transplant
  contributor:
    fullname: Bloom
– volume: 34
  start-page: P2492
  year: 2019
  end-page: P2500
  ident: bib0006
  article-title: High-risk and hepatitis C-Positive organ donors: current practice in heart, lung, and liver transplantation
  publication-title: J Cardiothorac Vasc Anesth
  contributor:
    fullname: Markin
– volume: 39
  start-page: P418
  year: 2020
  end-page: P432
  ident: bib0023
  article-title: Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement
  publication-title: J Heart Lung Transplant
  contributor:
    fullname: Schlendorf
– volume: 2
  start-page: 443
  year: 2002
  end-page: 447
  ident: bib0025
  article-title: Hepatitis C-positive donors in heart transplantation
  publication-title: Am J Transplant
  contributor:
    fullname: Laks
– volume: 4
  start-page: 771
  year: 2019
  end-page: 780
  ident: bib0009
  article-title: Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study
  publication-title: Lancet Gastroenterol Hepatol
  contributor:
    fullname: Gustafson
– volume: 5
  start-page: e486
  year: 2019
  ident: bib0027
  article-title: Heart transplantation from hepatitis C-positive donors in the era of direct acting antiviral therapy: a comprehensive literature review
  publication-title: Transplant Direct
  contributor:
    fullname: Nila
– volume: 6
  year: 2009
  ident: bib0022
  article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
  publication-title: PLoS Med
  contributor:
    fullname: Group
– volume: 9
  start-page: e014495
  year: 2020
  ident: bib0029
  article-title: Outcomes of adult heart transplantation using hepatitis C–positive donors
  publication-title: J Am Heart Assoc
  contributor:
    fullname: Mathier
– volume: 32
  start-page: e13308
  year: 2018
  ident: bib0021
  article-title: Accepting hepatitis C virus-infected donor hearts for transplantation: Multistep consent, unrealized opportunity, and the Stanford experience
  publication-title: Clin Transplant
  contributor:
    fullname: Khush
– volume: 71
  start-page: 686
  year: 2020
  end-page: 721
  ident: bib0008
  article-title: Panel A-IHCG. Hepatitis C Guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection
  publication-title: Hepatology
  contributor:
    fullname: Morgan
– volume: 51
  start-page: 865
  year: 2019
  end-page: 870
  ident: bib0018
  article-title: Heart transplantation in systemic sclerosis: new impulses for conventional scleroderma transplantation regimen and scleroderma diagnostic monitoring: 2 case reports
  publication-title: Transplant Proc
  contributor:
    fullname: Fujita
– volume: 11
  year: 2018
  ident: bib0030
  article-title: Current use of hearts from hepatitis C viremic donors
  publication-title: Circ Heart Fail
  contributor:
    fullname: Gulamhusein
– volume: 38
  start-page: 1259
  year: 2019
  end-page: 1267
  ident: bib0017
  article-title: Outcomes of heart transplantation from hepatitis C virus–positive donors
  publication-title: J Heart Lung Transplant
  contributor:
    fullname: Adler
– volume: 23
  start-page: 765
  year: 2017
  ident: 10.1016/j.healun.2022.01.010_bib0019
  article-title: Rational heart transplant from a hepatitis C donor: new antiviral weapons conquer the trojan horse
  publication-title: J Card Fail
  doi: 10.1016/j.cardfail.2017.08.448
  contributor:
    fullname: Gottlieb
– volume: 38
  start-page: 1178
  year: 2019
  ident: 10.1016/j.healun.2022.01.010_bib0002
  article-title: The impact of using hepatitis C virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate
  publication-title: J Heart Lung Transplant
  doi: 10.1016/j.healun.2019.08.010
  contributor:
    fullname: Gernhofer
– volume: 380
  start-page: 1606
  year: 2019
  ident: 10.1016/j.healun.2022.01.010_bib0011
  article-title: Heart and lung transplants from HCV infected donors to uninfected recipients
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1812406
  contributor:
    fullname: Woolley
– volume: 32
  start-page: e13308
  year: 2018
  ident: 10.1016/j.healun.2022.01.010_bib0021
  article-title: Accepting hepatitis C virus-infected donor hearts for transplantation: Multistep consent, unrealized opportunity, and the Stanford experience
  publication-title: Clin Transplant
  doi: 10.1111/ctr.13308
  contributor:
    fullname: Moayedi
– volume: 34
  start-page: e13764
  year: 2020
  ident: 10.1016/j.healun.2022.01.010_bib0013
  article-title: Hepatitis C donor viremic cardiac transplantation: a practical approach
  publication-title: Clin Transplant
  doi: 10.1111/ctr.13764
  contributor:
    fullname: Morris
– volume: 20
  start-page: 340
  issue: s1
  year: 2020
  ident: 10.1016/j.healun.2022.01.010_bib0028
  article-title: OPTN/SRTR 2018 annual data report: heart
  publication-title: Am J Transplant
  doi: 10.1111/ajt.15676
  contributor:
    fullname: Colvin
– volume: 17
  start-page: 2790
  year: 2017
  ident: 10.1016/j.healun.2022.01.010_bib0001
  article-title: The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation
  publication-title: Am J Transplant
  doi: 10.1111/ajt.14381
  contributor:
    fullname: Levitsky
– volume: 5
  start-page: e486
  year: 2019
  ident: 10.1016/j.healun.2022.01.010_bib0027
  article-title: Heart transplantation from hepatitis C-positive donors in the era of direct acting antiviral therapy: a comprehensive literature review
  publication-title: Transplant Direct
  doi: 10.1097/TXD.0000000000000928
  contributor:
    fullname: Bruno
– volume: 72
  start-page: 32
  year: 2020
  ident: 10.1016/j.healun.2022.01.010_bib0020
  article-title: Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus–negative recipients: a real-world experience
  publication-title: Hepatology
  doi: 10.1002/hep.31011
  contributor:
    fullname: Kapila
– volume: 5
  start-page: 649
  year: 2020
  ident: 10.1016/j.healun.2022.01.010_bib0010
  article-title: Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(20)30081-9
  contributor:
    fullname: Feld
– volume: 27
  start-page: 179
  year: 2019
  ident: 10.1016/j.healun.2022.01.010_bib0012
  article-title: Heart transplantation for hepatitis C virus non-viremic recipients from hepatitis C virus viremic donors
  publication-title: Cardiol Rev
  doi: 10.1097/CRD.0000000000000255
  contributor:
    fullname: Frager
– volume: 4
  start-page: 771
  year: 2019
  ident: 10.1016/j.healun.2022.01.010_bib0009
  article-title: Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(19)30240-7
  contributor:
    fullname: Bethea
– volume: 38
  start-page: S132
  year: 2019
  ident: 10.1016/j.healun.2022.01.010_bib0003
  article-title: Cost effectiveness of using hepatitis C Virus (HCV)-viremic hearts for transplantation into HCV-negative recipients
  publication-title: J Heart Lung Transplant
  doi: 10.1016/j.healun.2019.01.313
  contributor:
    fullname: Logan
– volume: 39
  start-page: P418
  year: 2020
  ident: 10.1016/j.healun.2022.01.010_bib0023
  article-title: Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement
  publication-title: J Heart Lung Transplant
  doi: 10.1016/j.healun.2020.03.004
  contributor:
    fullname: Aslam
– volume: 158
  year: 2020
  ident: 10.1016/j.healun.2022.01.010_bib0004
  article-title: Implementation of HCV+ donor heart protocol produces net overall cost savings in cardiac transplantation
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(20)33980-9
  contributor:
    fullname: Wang
– volume: 71
  start-page: 686
  year: 2020
  ident: 10.1016/j.healun.2022.01.010_bib0008
  article-title: Panel A-IHCG. Hepatitis C Guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection
  publication-title: Hepatology
  doi: 10.1002/hep.31060
  contributor:
    fullname: Ghany
– volume: 6
  year: 2009
  ident: 10.1016/j.healun.2022.01.010_bib0022
  article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1000097
  contributor:
    fullname: Moher
– volume: 20
  start-page: 2867
  year: 2020
  ident: 10.1016/j.healun.2022.01.010_bib0031
  article-title: Local and regional variability in utilization and allocation of hepatitis C virus-infected hearts for transplantation
  publication-title: Am J Transplant
  doi: 10.1111/ajt.15857
  contributor:
    fullname: Prakash
– volume: 51
  start-page: 865
  year: 2019
  ident: 10.1016/j.healun.2022.01.010_bib0018
  article-title: Heart transplantation in systemic sclerosis: new impulses for conventional scleroderma transplantation regimen and scleroderma diagnostic monitoring: 2 case reports
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2019.01.025
  contributor:
    fullname: Faust
– volume: 11
  year: 2018
  ident: 10.1016/j.healun.2022.01.010_bib0030
  article-title: Current use of hearts from hepatitis C viremic donors
  publication-title: Circ Heart Fail
  doi: 10.1161/CIRCHEARTFAILURE.118.005276
  contributor:
    fullname: Moayedi
– volume: 19
  start-page: 2533
  year: 2019
  ident: 10.1016/j.healun.2022.01.010_bib0014
  article-title: Transplanting hepatitis C virus-infected hearts into uninfected recipients: a single-arm trial
  publication-title: Am J Transplant
  doi: 10.1111/ajt.15311
  contributor:
    fullname: McLean
– volume: 38
  start-page: 1259
  year: 2019
  ident: 10.1016/j.healun.2022.01.010_bib0017
  article-title: Outcomes of heart transplantation from hepatitis C virus–positive donors
  publication-title: J Heart Lung Transplant
  doi: 10.1016/j.healun.2019.08.019
  contributor:
    fullname: Aslam
– volume: 9
  start-page: e014495
  year: 2020
  ident: 10.1016/j.healun.2022.01.010_bib0029
  article-title: Outcomes of adult heart transplantation using hepatitis C–positive donors
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.119.014495
  contributor:
    fullname: Kilic
– volume: 296
  start-page: 1843
  year: 2006
  ident: 10.1016/j.healun.2022.01.010_bib0005
  article-title: Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients
  publication-title: JAMA
  doi: 10.1001/jama.296.15.1843
  contributor:
    fullname: Gasink
– volume: 34
  start-page: e13989
  year: 2020
  ident: 10.1016/j.healun.2022.01.010_bib0016
  article-title: Outcomes of the treatment with glecaprevir/pibrentasvir following heart transplantation utilizing hepatitis C viremic donors
  publication-title: Clin Transplant
  doi: 10.1111/ctr.13989
  contributor:
    fullname: Reyentovich
– volume: 19
  start-page: 350
  year: 2000
  ident: 10.1016/j.healun.2022.01.010_bib0026
  article-title: Hepatitis C transmission and infection by orthotopic heart transplantation
  publication-title: J Heart Lung Transplant
  doi: 10.1016/S1053-2498(00)00062-0
  contributor:
    fullname: Pfau
– volume: 2
  start-page: 443
  year: 2002
  ident: 10.1016/j.healun.2022.01.010_bib0025
  article-title: Hepatitis C-positive donors in heart transplantation
  publication-title: Am J Transplant
  doi: 10.1034/j.1600-6143.2002.20508.x
  contributor:
    fullname: Marelli
– volume: 15
  start-page: 154
  year: 2016
  ident: 10.1016/j.healun.2022.01.010_bib0024
  article-title: Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: a concise review
  publication-title: Ann Hepatol
  contributor:
    fullname: Burgess
– volume: 5
  start-page: 167
  year: 2019
  ident: 10.1016/j.healun.2022.01.010_bib0015
  article-title: Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C
  publication-title: JAMA Cardiol
  doi: 10.1001/jamacardio.2019.4748
  contributor:
    fullname: Schlendorf
– volume: 34
  start-page: P2492
  year: 2019
  ident: 10.1016/j.healun.2022.01.010_bib0006
  article-title: High-risk and hepatitis C-Positive organ donors: current practice in heart, lung, and liver transplantation
  publication-title: J Cardiothorac Vasc Anesth
  doi: 10.1053/j.jvca.2019.12.012
  contributor:
    fullname: Chacon
– volume: 166
  start-page: 637
  year: 2017
  ident: 10.1016/j.healun.2022.01.010_bib0007
  article-title: Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review
  publication-title: Ann Intern Med
  doi: 10.7326/M16-2575
  contributor:
    fullname: Falade-Nwulia
SSID ssj0002352
Score 2.4345243
SecondaryResourceType review_article
Snippet Heart transplantation (HTx) from hepatitis C virus (HCV)-viremic donors to nonviremic recipients decreases mortality and costs. Consequently, many transplant...
BACKGROUNDHeart transplantation (HTx) from hepatitis C virus (HCV)-viremic donors to nonviremic recipients decreases mortality and costs. Consequently, many...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 538
SubjectTerms Antiviral Agents - therapeutic use
cardiac transplantation
direct-acting antivirals
Heart Transplantation
Hepacivirus
Hepatitis C - drug therapy
hepatitis c non-viremic recipients
hepatitis c viremic donors
hepatitis c virus
Hepatitis C, Chronic - drug therapy
Humans
nucleic acid amplification test
Tissue Donors
Title Clinical outcomes of heart transplantation using hepatitis c-viremic donors: A systematic review with meta-analysis
URI https://dx.doi.org/10.1016/j.healun.2022.01.010
https://www.ncbi.nlm.nih.gov/pubmed/35153130
https://search.proquest.com/docview/2628695119
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZ-rKXsbFbdkODvQ0V27KdeG-h9MJ6GYxky5uQZGlryexS2xnrr9-RJdluu7JuEEwQSDH6vhx9OjrnCKF3sKjqANY5ImOqCVjJHOxgSkmYyohrpWGVNQ7945P0YBl_XCWr0WgziFpqarEtL_-YV_I_qEIb4GqyZP8B2W5QaIDvgC88AWF43gnjHZ_WWDY1jG_rx5orqmtz9UNRna954aIJm9Yn8F2ZAOr6tHovyQaMnQmMz8uivKhshvr1us4_rZ_2h6o54a58yVDO9oll6_6njSt-3djrJ4bv4LH9YtIPv_GK7PM135xeuoOIpidfm3DjLhnZdM37IPVtxYNj_osP3RWw0-2jXJQzsYnxjNqMTW-DbfErx7V4YFATW_vFrc2JLW96w-xbD8TZthHXjalqG0VtMVYXMXulyvbJJ7a3PDpii93V4h7aMgUU4zHamh9-_nrYreER6FKfaNlGA94c-TYhc9tGpRUsi4fogYMFzy1tHqGRKh6jylMGe8rgUuMWN3wNLtxSBneUwR1lsKXMBzzHPWGwJQw2hMFXCPMELfd2FzsHxN27QSTImZrAX1TTKexn4izOQ8mVpCCUgzwWJsAu4VEoNBigNjp6ms8CEaSZyEEoy0wmKhT0KRoXZaGeIwybA-gpZjPNRZxqyoNIBrGgmZ7mnEf5BBE_iezclldhPu7wjNlJZ2bSWRDCJ5igqZ9p5iSilX4MqPCXnm89MAwsqDkW44Uqm4pFJjs7M-fpE_TMIta9CwW5T0HmvbhD75fofk_4V2hcXzTqNSjWWrxx9PoNJ1ig8w
link.rule.ids 314,780,784,27924,27925
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+outcomes+of+heart+transplantation+using+hepatitis+c-viremic+donors%3A+A+systematic+review+with+meta-analysis&rft.jtitle=The+Journal+of+heart+and+lung+transplantation&rft.au=Villegas-Galaviz%2C+Josue&rft.au=Anderson%2C+Eve&rft.au=Guglin%2C+Maya&rft.date=2022-04-01&rft.eissn=1557-3117&rft.volume=41&rft.issue=4&rft.spage=538&rft.epage=549&rft_id=info:doi/10.1016%2Fj.healun.2022.01.010&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1053-2498&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1053-2498&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1053-2498&client=summon